Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nanjing Zenshine Pharmaceuticals Co. Ltd. is currently navigating 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This activity is confined to 1 distinct examiner and 1 distinct art unit, reflecting a focused examination path. In the complex field of biotechnology, having only 1 pending action suggests a highly targeted approach to the current patent filings.
GENBIN SHI is the busiest examiner for the portfolio, currently overseeing 1 pending office action. This 1 busiest examiner pending action accounts for the total pending workload of the company, as the busiest examiner pending count is 1. Practitioners should note that the prosecution progress for the entire portfolio is currently tied to this single examiner's review. The concentration in 1 distinct art unit indicates that the company is not currently managing cross-disciplinary filings that would require coordination across different pharmaceutical examination groups.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHI, GENBIN | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18716156 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | SHI, GENBIN | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18716156 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | SHI, GENBIN | 1628 | §103§112 | Non-Final OA | — | Pending | Jun 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNanjing Zenshine Pharmaceuticals Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Genbin Shi has the most, with 1 of Nanjing Zenshine Pharmaceuticals Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
